2013•Bioorganic & Medicinal Chemistry LettersRequires access

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses

Bernard Côté, Jason D. Burch, Ernest Asante‐Appiah, Chris Bayly, Leanne L. Bedard, Marc Blouin, Louis‐Charles Campeau, Elizabeth Cauchon, Manuel Chan, Amandine Chefson, Nathalie Coulombe, Wanda Cromlish, Smita Debnath, Denis Deschênes, Kristina Dupont‐Gaudet, Jean‐Pierre Falgueyret, Robert Forget, Sébastien Gagné, Danny Gauvreau, Mélina Girardin, Sébastien Guiral, Eric Langlois, Chun Sing Li, Natalie Nguyen, Rob Papp, Serge Plamondon, Amélie Roy, Stéphanie Roy, Ria Seliniotakis, Miguel St‐Onge, Stéphane G. Ouellet, Paul Tawa, Jean‐François Truchon, Joe P. Vacca, Marc Wrona, Youwei Yan, Yves Ducharme

Open publisher page 104 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 104 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Reverse transcriptase, Reverse-transcriptase inhibitor, Nucleoside Reverse Transcriptase Inhibitor, Nucleoside, Mutant, Chemistry, Virology, Nucleotidyltransferase